Erratum to: Screening Tool for Older Persons' Appropriate Prescriptions for Japanese: Report of the Japan Geriatrics Society Working Group on “Guidelines for medical treatment and its safety in the elderly” (Geriatr Gerontol Int, (2016), 16, 983-1001, 10.1111/ggi.12890);Screening Tool for Older Persons’ Appropriate Prescriptions in Japanese: Report of the Japan Geriatrics Society Working Group on “Guidelines for medical treatment and its safety in the elderly”

Geriatrics and Gerontology International

Volumn 16, Issue 9, 2016, Pages 983-1001

  Kojima, Taro ^a   Mizukami, Katsuyoshi ^b   Tomita, Naoki ^c   Arai, Hiroyuki ^c   Ohrui, Takashi ^c   Eto, Masato ^a   Takeya, Yasushi ^d   Isaka, Yoshitaka ^d   Rakugi, Hiromi ^d   Sudo, Noriko ^e   Arai, Hidenori ^f   Aoki, Hiroaki ^g   Horie, Shigeo ^g   Ishii, Shinya ^a   Iwasaki, Koh ^h   Takayama, Shin ⁱ   Suzuki, Yusuke ^j   Matsui, Toshifumi ^k   Mizokami, Fumihiro ^f   Furuta, Katsunori ^f   Toba, Kenji ^c   Akishita, Masahiro ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Mutual Aid Association of Public School Teachers   (Japan)

^f NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^g JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Ishinomaki Ogatsu Municipal Clinic   (Japan)

ⁱ TOHOKU UNIVERSITY HOSPITAL   (Japan)

^j NAGOYA UNIVERSITY HOSPITAL   (Japan)

^k KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIGUANIDE; CHLORPHENIRAMINE; CHLORPROMAZINE; DIAZEPAM; DIGOXIN; DIPHENHYDRAMINE; DIURETIC AGENT; EPLERENONE; ETIZOLAM; FLURAZEPAM; FUROSEMIDE; HALOPERIDOL; HALOXAZOLAM; LEVOMEPROMAZINE; MAGNESIUM OXIDE; OLANZAPINE; PEROSPIRONE; PIOGLITAZONE; QUETIAPINE; RISPERIDONE; SPIRONOLACTONE; TERAZOSIN; TRIAZOLAM; TRIPROLIDINE; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

AGED; AGING; APPROPRIATE PRESCRIBING; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; DEMENTIA; DEPRESSION; DIARRHEA; DIGITALIS INTOXICATION; DRUG FATALITY; DRUG THERAPY; ELECTROLYTE DISTURBANCE; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GERIATRIC CARE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; INSOMNIA; JAPAN; JAPANESE (PEOPLE); KIDNEY FAILURE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARKINSON DISEASE; PNEUMONIA; POTENTIALLY INAPPROPRIATE MEDICATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RHEUMATOID ARTHRITIS; SCREENING TEST; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; VERY ELDERLY; XEROSTOMIA;

EID: 84985034729     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.13023     Document Type: Erratum

References (130)

1. The Japan Geriatrics Society. Guidelines for medical treatment and its safety in the elderly 2005. Tokyo: Medical View Co., Ltd., 2005 (in Japanese).
2. Ishii S, Kojima T, Yamaguchi K et al. Guidance statement on appropriate medical services for the elderly. Geriatr Geront Int 2014; 14: 518–525.
3. http://www.gradeworkinggroup.org/
4. http://minds4.jcqhc.or.jp/minds/guideline/pdf/MindsHB2014.pdf
5. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616–631.
6. Gallagher P, Ryan C, Byrne S et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008; 462: 72–83.
7. O'Mahony D, O'Sullivan D, Byrne S et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015; 44: 213–218.
8. Statement on Frailty by the Japan Geriatrics Society. Available at http://www.jpn-geriat-soc.or.jp/info/topics/pdf/20140513_01_01.pdf. (in Japanese)
9. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191–210.
10. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 2006; 54: 354–361.
11. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Am J Alzheimers Dis Other Demen 2011; 26: 10–28.
12. Iersel MB, Zuidema SU, Koopmans RT, Verhey FR, Rikkert MG. Antipsychotics for behavioral and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging 2005; 22: 845–858.
13. Lertxundi U, Ruiz AI, Aspiazu MÁ et al. Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish pharmacovigilance database. Clin Neuropharmacol 2015; 38: 69–84.
14. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331 (7526): 1169.
15. Hsiao FY, Peng LN, Lin MH, Chen LK. Dose-responsive effect of psychotropic drug use and subsequent dementia: a nationwide propensity score matched case-control study in Taiwan. J Am Med Dir Assoc 2014; 15: 509–513.
16. Zhong G, Wang Y, Zhang Y, Zhao Y. Association between benzodiazepine use and dementia: a meta-analysis. PLoS One 2015; 10 e0127836.
17. Berry SD, Lee Y, Cai S et al. Non-benzodiazepine sleep medications and hip fractures in nursing home residents. JAMA Intern Med 2013; 173: 754–761.
18. Kang DY, Park S, Rhee CW et al. Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health 2012; 45: 219–226.
19. Limosin F, Samuelian JC, Rouillon F. Multicenter double-blind study of the efficacy of paroxetine versus clomipramine in elderly patients with major depression. J Aging Pharmacother 2007; 13: 7–19.
20. K W, P M. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004; 19: 754–762.
21. Talley NJ, Jones M, Nuyts G et al. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003; 98: 1107–1111.
22. Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry 2007; 52: 248–255.
23. Field TS, Gurwitz JH, Avorn J et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161: 1629–1634.
24. Jiang HY, Chen HZ, Hu XJ et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 42–50 e3.
25. Dogmatil Medicine Interview Form, April 2014. (in Japanese)
26. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br J Clin Pharmacol 2015; 80: 209–220.
27. Edited by the Committee on Making the Clinical Practice Guideline for Parkinson's Disease. Clinical Practice Guideline for Parkinson's Disease. Tokyo: Igaku-Shoin, Ltd., 2011 (in Japanese).
28. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003; 2 CD003735.
29. Committee for the Fourth Edition of the COPD Guidelines of the Japanese Respiratory Society. Guidelines for the Diagnosis and Treatment of COPD, 4th edn. Tokyo: Medical Review Co., Ltd, 2013 (in Japanese).
30. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2015. Available at: http://www.goldcopd.org/.
31. Horita N, Miyazawa N, Morita S et al. Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease. Respir Res 2014; 15: 37.
32. JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J 2014; 78: 1997–2021.
33. The Japan Stroke Study. The Japanese guidelines for the management of stroke 2015. Tokyo: Kyowa Kikaku, Ltd, 2015.
34. JCS Joint Working Group. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009). Available at http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf. (in Japanese)
35. JCS Joint Working Group. Guidelines for elective percutaneous coronary intervention in patients with stable coronary artery disease (JCS 2011) published in 2012--digest version. Circ J 2013; 77: 1590–1607.
36. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–533.
37. Misiaszek B, Heckman GA, Merali F et al. Digoxin prescribing for heart failure in elderly residents of long-term care facilities. Can J Cardiol 2005; 21: 281–286.
38. Ahmed A, Young JB, Love TE et al. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008; 125: 246–253.
39. Maeder MT, Rickli H, Pfisterer ME et al. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J 2012; 163: 407–414 414.e1.
40. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M et al. Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2012; 76: 1920–1927.
41. Lim LS, Fink HA, Kuskowski MA et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 2008; 168: 735–740.
42. Lim LS, Fink HA, Blackwell T et al. Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J Am Geriatr Soc 2009; 57: 855–862.
43. Sirkin AJ, Rosner NG. Hypertensive management in the elderly patient at risk for falls. J Am Acad Nurse Pract 2009; 21: 402–408.
44. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996; 44: 194–197.
45. Furniss L, Craig SK, Burns A. Medication use in nursing homes for elderly people. Int J Geriatr Psychiatry 1998; 13: 433–439.
46. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–551.
47. Ko DT, Juurlink DN, Mamdani MM et al. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail 2006; 12: 205–210.
48. Muzzarelli S, Maeder MT, Toggweiler S et al. Frequency and predictors of hyperkalemia in patients 60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol 2012; 109: 693–698.
49. Rossignol P, Dobre D, McMurray JJ et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014; 7: 51–58.
50. Krum H, Roecker EB, Mohacsi P et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289: 712–718.
51. Shimamoto K, Ando K, Fujita T. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253–387.
52. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780–1787.
53. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother 2008; 42: 523–532.
54. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999; 21: 101–122.
55. World Gastroenterology Organisation Global Guideline. Constipation - A Global Perspective. J Clin Gastroenterol 2011; 45: 483–487.
56. Moore AR et al. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15: 15–28.
57. Boustani M et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc 2007; 55: 1248–1253.
58. Gray SL et al. Histamine-2 receptor antagonist use and incident dementia in an older cohort. J Am Geriatr Soc 2011; 59: 251–257.
59. Hanlon JT, Landerman LR, Artz MB et al. Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly. Pharmacoepidemiol Drug Saf 2004; 13: 781–787.
60. Fujii S et al. Comparison and analysis of delirium induced by histamine H2 receptor antagonists and proton pump inhibitors in cancer patients. Case Rep Oncol 2012; 5: 409–412.
61. Bondon-Guitton E, Perez-Lloret S, Bagheri H et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26: 2226–2231.
62. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009; 85: 322–326.
63. Saito N. Effect of renal dysfunction and of administering magnesium oxide on serum magnesium levels in elderly hospitalized patients. Nihon Ronen Igakkai Zasshi 2011; 48: 263–270.
64. Kinnunen O et.al. Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. Ann Clin Res 1987; 19: 321–313.
65. http://www.jds.or.jp/uploads/photos/797.pdf
66. Committee on Indications for Using Biguanide Medication: Recommendation on indications for using biguanide medication (revised March 28th, 2014). Available at http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025_7265636F6D6D656E646174696F6E5F62696775616E6964652E706466
67. Ito H, Ohno Y, Yamauchi T et al. Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients. Geriatr Gerontol Int 2011; 11: 55–62.
68. Penfornis A, Bourdel-Marchasson I, Quere S et al. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab 2012; 38: 550–557.
69. American Geriatrics Society Guidelines for Improving the Care of the Older Adult with Diabetes Mellitus: 2013 Update.
70. Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–590.
71. Lipscombe LL, Gomes T, Levesque LE et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634–2643.
72. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349–3354.
73. Solomon DH, Cadarette SM, Choudhry NK et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009; 94: 2792–2798.
74. Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–2443.
75. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32–39.
76. Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PRoactive 08). Diabetes Care 2007; 30: 2773–2778.
77. Dormandy J, Bhattacharya M. van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187–202.
78. Josse RG, Chiasson JL, Ryan EA et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003; 59: 37–42.
79. Committee on Indications for Using SGLT2 Inhibitors. Recommendation on indications for using SGLT2 inhibitors (revised August 29th, 2014). Available at http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025_7265636F6D6D656E646174696F6E5F53474C54322E706466 (accessed 2014-12-18).
80. Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events. J Am Geriatr Soc 2011; 59: 1332–1339.
81. Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011; 12: 351–357.
82. Capo JP, Lucente V, Forero-Schwanhaeuser S et al. Efficacy and tolerability of solifenacin in patients aged 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Postgrad Med 2011; 123: 94–104.
83. Yamaguchi O, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology 2011; 78: 126–133.
84. Kraus SR, Ruiz-Cerdá JL, Martire D et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76: 1350–1357.
85. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14–24.
86. Kessler TM, Bachmann LM, Minder C et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011;23; 6 (2e16718).
87. Kaplan SA, He W, Koltun WD, Cummings J et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013; 63: 158–165.
88. Lee KS, Choo MS, Kim DY et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174 (4 Pt 1): 1334–1338.
89. The Japanese Continence Society. Clinical guidelines for overactive bladder, 2nd edn. Tokyo: Richhill Medical Inc, 2015 (in Japanese).
90. Wagg A, Khullar V, Marschall-Kehrel D et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013; 61: 185–193.
91. Dubeau CE, Kraus SR, Griebling TL et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol 2014; 191: 395–404.
92. Wagg A, Dale M, Tretter R et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013; 64: 74–81.
93. Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J 1999; 92: 485–490.
94. Murray MD, Black PK, Kuzmik DD et al. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995; 310: 188–197.
95. Henry D, Page J, Whyte I et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol 1997; 44: 85–90.
96. Simon LS, Basch CM, Young DY et al. Effects of naproxen on renal function in older patients with mild to moderate renal dysfunction. Br J Rheumatol 1992; 31: 163–168.
97. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488–496.
98. Juhlin T, Björkman S, Höglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail 2005; 7: 1049–1056.
99. Adhiyaman V, Asghar M, Oke A et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001; 94: 512–514.
100. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–1255.
101. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–249.
102. Chan FK, Wong VW, Suen BY et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–1626.
103. Koch M, Dezi A, Tarquini M et al. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis 2000; 32: 138–151.
104. Stowe RL, Ives NJ, Clarke C et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008; 2 CD006564.
105. Nichol KL, Nordin JD, Nelson DB et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357: 1373–1381.
106. Bonten MJ, Huijts SM, Bolkenbaas M et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114–1125.
107. Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189–195.
108. Kawakami K, Ohkusa Y, Kuroki R et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010; 28: 7063–7069.
109. Aspiration Pulmonary Disease Study Group: Diagnosis and treatment for aspiration pulmonary disease (revised). Tokyo; Pfizer, 2013.
110. Gianni M, Bosch J, Pogue J et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J 2007; 28: 1382–1388.
111. Ahmed A, Centor RM, Weaver MT et al. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005; 149: 737–743.
112. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166: 659–666.
113. Heywood JT, Fonarow GC, Yancy CW et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol 2000; 105: 1140–1146.
114. Solh AA, Saliba R. Pharmacologic prevention of aspiration pneumonia: a systematic review. Am J Geriatr Pharmacother 2007; 5: 352–362.
115. Caldeira D, Alarcao J, Vaz-Carneiro A et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012; 345 e4260.
116. Kitzman DW, Hundley WG, Brubaker PH et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010; 3: 477–485.
117. Cohen-Solal A, McMurray JJ, Swedberg K et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Eur Heart J 2008; 29: 3022–3028.
118. White HD, Aylward PE, Huang Z et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005; 112: 3391–3399.
119. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guideline for prevention of atherosclerotic cardiovascular diseases 2012. J Atheroscler Thromb 2014; 21 (Suppl.2): 1–118.
120. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007; 62: 879–887.
121. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
122. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.
123. Shepherd J, Blauw GJ, Murphy MB et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 3 (360): 1623–1630.
124. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634–2640.
125. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005; 95: 354–357.
126. Miyakita H, Yokoyama E, Onodera Y et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol 2010; 17: 869–875.
127. Yokoyama T, Hara R, Fukumoto K et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol 2011; 18: 225–230.
128. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492–509.
129. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625–639.
130. Diaz-Borjon A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging 2009; 26: 273–293.